Novartis: acquires Anthos Therapeutics

(CercleFinance.com) - Novartis announces an agreement to acquire Anthos Therapeutics, an unlisted clinical-stage biopharmaceutical company based in Boston, a transaction expected to close in H1 2025, subject to customary conditions.


Anthos holds abelacimab, currently in phase 3 development, with the lead indication for the prevention of stroke and systemic embolism in patients with atrial fibrillation.

Under the terms of the agreement, Novartis will make an upfront payment of $925m at closing, subject to certain customary adjustments, as well as potential additional payments of up to $2.15bn.


Copyright (c) 2025 CercleFinance.com. All rights reserved.